Approved Indications for Biosimilar Inflectra

April 8, 2016
Rheumatology Network Staff

In this slideshow, we summarize the approved indications for the rheumatology biosimilar Inflectra (infliximab-dyyb), the boxed warnings and possible side effects.

The U.S. Food and Drug Administration approved Inflectra (infliximab-dyyb) on April 5, 2016 for six indications. Prescribing information from the FDA: